Download PDF
Endoscopy 2021; 53(07): 732-736
DOI: 10.1055/a-1255-9169
Innovations and brief communications

Volatile organic compounds in bile can distinguish pancreatic cancer from chronic pancreatitis: a prospective observational study

Udayakumar Navaneethan
1   Center for Interventional Endoscopy, Orlando, Florida, United States
,
Chad Spencer
2   Department of Gastroenterology and Hepatology, University of South Alabama College of Medicine, Mobile, Alabama, United States
,
Xiang Zhu
3   Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, United States
,
John J. Vargo
4   Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland, Ohio, United States
,
David Grove
5   Pathobiology, Lerners Research Institute, Cleveland Clinic, Cleveland, Ohio, United States
,
Raed A. Dweik
5   Pathobiology, Lerners Research Institute, Cleveland Clinic, Cleveland, Ohio, United States
› Author AffiliationsTrial Registration: ClinicalTrials.gov Registration number (trial ID): NCT02531607 Type of study: prospective study
› Further Information
Also available at
    Permissions and Reprints

Referred to by:

Bile volatile organic compounds, smelling troubleEndoscopy 2021; 53(07): 737-738
DOI: 10.1055/a-1312-6330

Abstract

Background Early and accurate diagnosis of pancreatic cancer is important. Our aim was to identify potential volatile organic compounds (VOCs) in the bile that can help distinguish pancreatic cancer from chronic pancreatitis.

Methods In this prospective observational study, bile was aspirated from patients undergoing endoscopic retrograde cholangiopancreatography for chronic pancreatitis and pancreatic cancer, and the gaseous headspace was analyzed using mass spectrometry.

Results The study included a discovery cohort of 57 patients (46 pancreatic cancer, 11 chronic pancreatitis) and a validation cohort of 31 patients (19 and 12, respectively). Using logistic regression analysis, the model [0.158 × age + 9.747 × log (ammonia) – 3.994 × log (acetonitrile) + 5.044 × log (trimethylamine) – 30.23] successfully identified patients with pancreatic cancer with a sensitivity of 93.5 % and specificity of 100 % (likelihood ratio 40.9, area under the curve 0.98, 95 % confidence interval 0.95 – 1.00). The diagnostic accuracy of this model was confirmed in the second independent validation cohort.

Conclusion The measurement of VOCs in bile helped to accurately distinguish pancreatic cancer from chronic pancreatitis.

Supplementary material



Publication History

Received: 12 May 2020

Accepted: 04 September 2020

Accepted Manuscript online:
04 September 2020

Article published online:
24 June 2021

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013; 144: 1252-1261
    CrossrefPubMedSearch in Google Scholar
  • 2 Mayerle J, Kalthoff H, Reszka R. et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut 2018; 67: 128-137
    CrossrefPubMedSearch in Google Scholar
  • 3 Navaneethan U, Parsi MA, Gutierrez NG. et al. Volatile organic compounds in bile can diagnose malignant biliary strictures in the setting of pancreatic cancer: a preliminary observation. Gastrointest Endosc 2014; 80: 1038-1045
    CrossrefPubMedSearch in Google Scholar
  • 4 Ahmed I, Fayyaz F, Nasir M. et al. Extending landscape of volatile metabolites as novel diagnostic biomarkers of inflammatory bowel disease – a review. Scand J Gastroenterol 2016; 51: 385-392
    CrossrefPubMedSearch in Google Scholar
  • 5 Di Lena M, Porcelli F, Altomare DF. Volatile organic compounds as new biomarkers for colorectal cancer: a review. Colorectal Dis 2016; 18: 654-663
    CrossrefPubMedSearch in Google Scholar
  • 6 Turner C. Techniques and issues in breath and clinical sample headspace analysis for disease diagnosis. Bioanalysis 2016; 8: 677-690
    CrossrefPubMedSearch in Google Scholar
  • 7 Paschke KM, Mashir A, Dweik RA. Clinical applications of breath testing. F1000 Med Rep 2010; 2: 56
    CrossrefPubMedSearch in Google Scholar
  • 8 Smith D, Spanel P. Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. Mass Spectrom Rev 2005; 24: 661-700
    CrossrefPubMedSearch in Google Scholar
  • 9 Amelio I, Cutruzzolá F, Antonov A. et al. Serine and glycine metabolism in cancer. Trends Biochem Sci 2014; 39: 191-198
    CrossrefPubMedSearch in Google Scholar
  • 10 DeBerardinis RJ, Mancuso A, Daikhin E. et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007; 104: 19345-19350
    CrossrefPubMedSearch in Google Scholar
  • 11 Chhibber-Goel J, Gaur A, Singhal V. et al. The complex metabolism of trimethylamine in humans: endogenous and exogenous sources. Expert Rev Mol Med 2016; 18: e8
    CrossrefPubMedSearch in Google Scholar
  • 12 Tesiram YA, Lerner M, Stewart C. et al. Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies. Pancreas 2012; 41: 474-480
    CrossrefPubMedSearch in Google Scholar
  • 13 Velasquez MT, Ramezani A, Manal A. et al. Trimethylamine N-oxide: the good, the bad and the unknown. Toxins (Basel) 2016; 8: 326
    CrossrefPubMedSearch in Google Scholar
  • 14 Houeto P, Hoffman JR, Got P. et al. Acetonitrile as a possible marker of current cigarette smoking. Hum Exp Toxicol 1997; 16: 658-661
    CrossrefPubMedSearch in Google Scholar
  • 15 Iodice S, Gandini S, Maisonneuve P. et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Lagenbecks Arch Surg 2008; 393: 535-545
    CrossrefPubMedSearch in Google Scholar
  • 16 Ye X, Lu G, Huai J. et al. Impact of smoking on the risk of pancreatitis: a systematic review and meta-analysis. PLoS One 2015; 10: e0124075
    CrossrefPubMedSearch in Google Scholar
  • 17 Seufferlein T, Mayerle J. Pancreatic cancer in 2015: Precision medicine in pancreatic cancer – fact or fiction?. Nat Rev Gastroenterol Hepatol 2016; 13: 74-75
    PubMedSearch in Google Scholar
  • 18 Ghatnekar O, Andersson R, Svensson M. et al. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. Int J Cancer 2013; 133: 2392-2397
    CrossrefPubMedSearch in Google Scholar
  • 19 Ligor M, Ligor T, Bajtarevic A. et al. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry. Clin Chem Lab Med 2009; 47: 550-560
    CrossrefPubMedSearch in Google Scholar
  • 20 Hietanen E, Bartsch H, Béréziat JC. et al. Diet and oxidative stress in breast, colon and prostate cancer patients: a case–control study. Eur J Clin Nutr 1994; 48: 575-586
    PubMedSearch in Google Scholar